Form 4: HCA Healthcare COO Granted Stock Appreciation Rights

HCA Healthcare's EVP and COO, Jon M. Foster, was granted 11,945 stock appreciation rights with a strike price of $482.53, vesting over four years.

Summary

• Jon M. Foster, EVP and COO of HCA Healthcare, Inc., acquired 11,945 Stock Appreciation Rights (SARs) on January 29, 2026.
• The SARs have a conversion or exercise price of $482.53 and an expiration date of January 29, 2036.
• These SARs will vest in four equal annual installments, commencing on January 29, 2027.
• Foster also beneficially owns 171,454 shares of Common Stock indirectly through various trusts.
• A Power of Attorney was executed on August 8, 2025, authorizing specific individuals to prepare and file SEC forms on Foster's behalf.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive incentive alignment and retention, without indicating any immediate operational or financial shifts.

Positives

• Grant of 11,945 Stock Appreciation Rights (SARs) to a key executive, Jon M. Foster, aligns management incentives with long-term shareholder value.
• The SARs have a long expiration date of January 29, 2036, providing a sustained long-term incentive for the executive.

Risks

• The Power of Attorney explicitly states that it does not relieve Jon M. Foster from responsibility for compliance with Exchange Act obligations, including reporting requirements under Section 16.

Future Outlook

The granted Stock Appreciation Rights are structured to vest in four equal annual installments starting January 29, 2027, providing a long-term incentive for the executive.

Management Comments

• "The undersigned hereby makes, constitutes and appoints John M. Franck II, Natalie Harrison Cline and Kevin A. Ball... as the undersigned's true and lawful attorneys-in-fact, with full power and authority... to prepare, execute, acknowledge, deliver and file Forms 3, 4 and 5..."
• "This Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act."

Industry Context

StockSavvy.ai notes that executive compensation, particularly through equity-based incentives like Stock Appreciation Rights, is a common practice in the healthcare industry to align executive performance with long-term shareholder value. The grant to a key operational executive like the COO suggests a focus on retaining top talent and incentivizing operational excellence within HCA Healthcare, a major player in the hospital sector.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership of Common Stock through JMF Trust (Spouse and Robert Nagel, Co-Trustees).
• Indirect beneficial ownership of Common Stock through LCF Trust (Reporting Person, Trustee).
• Indirect beneficial ownership of Common Stock through JMF Family Trust (Spouse, Trustee).
• Indirect beneficial ownership of Common Stock through 2025 GRAT.

Stakeholder Impact

• Shareholders: The grant of SARs aligns the interests of a key executive with shareholders, as the value of the SARs increases with the company's stock price.
• Management: The executive receives a significant equity incentive, potentially increasing motivation and retention.

Next Steps

• The Stock Appreciation Rights will vest in four equal annual installments beginning on January 29, 2027.
• The SARs will expire on January 29, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (grant of SARs) and does not provide new information that would fundamentally alter the investment thesis for HCA Healthcare. While the grant aligns executive incentives, it's a standard practice and not a catalyst for a 'buy' or 'sell' recommendation based solely on this filing. Investors should 'hold' and consider broader company fundamentals and market conditions.

Keywords

HCA Healthcare, HCA, Form 4, Insider Transaction, Stock Appreciation Rights, SARs, Executive Compensation, Jon M. Foster, Corporate Governance